RHB Investment Research Reports

IHH Healthcare - Ending the Year With Record High Revenue; Keep BUY

Publish date: Fri, 01 Mar 2024, 10:54 AM
0 3,523
An official blog in I3investor to publish research reports provided by RHB Research team.

All materials published here are prepared by RHB Investment Bank Bhd. For latest offers on RHB Invest trading products and news, please refer to: http://www.rhbinvest.com

RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur

Tel : +(60) 3 9280 8888
Fax : +(60) 3 9200 2216
  • Keep BUY, higher MYR7.50 TP (SOP) from MYR6.90, 22% upside. 4Q23 core profit came off by 28% QoQ to MYR266m (below expectations) amid a seasonally weaker quarter due to the holiday and festive seasons. We continue to like IHH Healthcare given its reputable regional footprint across key regions, its organic expansion target (+33% bed capacity by 2028), and resilient demand for healthcare services. It currently trades at 14.5x 2024F EV/EBITDA, 0.3SD below its 5-year historical mean.
  • Results overview. Full-year core earnings came in at 91% and 79% of our and Street’s estimates, which we deem as below expectations, no thanks to increases in staff and utilities costs, and a weakening TRY. Full-year hospital and healthcare toplines (all geographical regions) posted 21% YoY growth on strong recovery from non-COVID-19-related revenue, commencement of Atasehir Hospital, and consolidation of newly acquired hospitals in various regions. In 2023, IHH’s operational beds grew to 12,307 (2022: 11,881 beds). Group bed occupancy rate (BOR) contracted slightly (69% vs 2022’s 70%).
  • Segmental breakdown. Acibadem did well despite growing geopolitical tensions in the Middle East. Inpatient admissions spiked 13% QoQ (+2% YoY) thanks to the consolidation of newly acquired hospitals and improved performances from existing facilities. Malaysia revenue grew 13%, likely on better patient mix and an 8% YoY growth in inpatient admissions. Singapore BOR held up steadily, at 61% (3Q23: 62%) as concerns over nursing shortages was resolved gradually. On a group basis, all key geographic regions reported sequential lower inpatient admissions, except Turkey.
  • Outlook. IHH had revised upwards its dividend policy to no <30% of its core PATAMI from no <20% moving forward. Concurrently, it continues to uphold its bed expansion target over the next five year (+33% or 4,000 beds). We remain positive on IHH’s long-term prospects as we like the group’s solid execution strategy and reputable regional footprint across key regions – driven by its strong brand awareness, inelastic demand nature towards healthcare services, and focus on affluent clientele, which should provide earnings resiliency despite the challenging market environment.
  • Earnings estimate and valuation. Post 2023’s year-end book-keeping, our 2024-2025 earnings are raised by 2% and 1%. Maintain BUY with a higher TP of MYR7.50. Our TP implies 15.7x FY24F EV/EBITDA, which is in line with its 5-year historical average. We incorporate a 0% ESG premium to our intrinsic value as the ESG score is in line with the 3.0 country median. Key downside risks: Mandatory takeover offer overhang on Fortis, lower-than-expected patient volume/revenue intensity, and higher than expected operating costs.

Source: RHB Research - 1 Mar 2024

Related Stocks
Be the first to like this. Showing 0 of 0 comments

Post a Comment